Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01125566
Registration number
NCT01125566
Ethics application status
Date submitted
10/05/2010
Date registered
18/05/2010
Date last updated
18/07/2019
Titles & IDs
Public title
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
Query!
Scientific title
LUX-Breast 1; An Open Label, Randomised Phase III Trial of BIBW 2992 and Vinorelbine Versus Trastuzumab and Vinorelbine in Patients With Metastatic HER2-overexpressing Breast Cancer Failing One Prior Trastuzumab Treatment
Query!
Secondary ID [1]
0
0
2009-015476-98
Query!
Secondary ID [2]
0
0
1200.75
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Neoplasms
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - BIBW 2992
Treatment: Drugs - trastuzumab
Treatment: Drugs - vinorelbine
Treatment: Drugs - vinorelbine
Active comparator: Arm B: trastuzumab with vinorelbine - patients receive weekly intravenous infusion of trastuzumab and vinorelbine
Experimental: Arm A: BIBW 2992 with vinorelbine - patients receive BIBW 2992 tablets once daily combined with weekly intravenous infusion of vinorelbine
Treatment: Drugs: BIBW 2992
patients receive BIBW 2992 tablets once daily and can reduce dose for adverse event management
Treatment: Drugs: trastuzumab
patients receive trastuzumab 2mg/kg intravenously every week
Treatment: Drugs: vinorelbine
patients receive vinorelbine 25mg/m² intravenously every week
Treatment: Drugs: vinorelbine
patients receive vinorelbine 25mg/m² intravenously every week
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS is defined as time from randomisation to disease progression or death whichever occurs first. Assessed by investigator according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1). RECIST is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize") or worsen ("progress") during treatment.
Only data collected until the cut-off date for RECIST 1.1 based endpoints (08Jun2013) were considered.
Progression of disease was determined if at least 1 of the following criteria applied:
* At least a 20% increase in the sum of the diameters (SoD) of target lesions taking as reference the smallest SoD recorded since the treatment started, together with an absolute increase in the SoD of at least 5 mm
* Appearance of 1 or more new lesions
* Unequivocal progression of existing non-target lesions
Query!
Timepoint [1]
0
0
From randomization (07Sep2010) until disease progression, death or data cut-off (08Jun2013); Up to 34 months
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS is defined as time from randomisation to death irrespective of the cause of the death.
For patients who had not died up to the cut-off date (03Sep2013), the date they were last known to be alive was derived from the patient status records, the trial completion record, radiological imaging assessments, the study treatment termination record, and the randomisation date.
Query!
Timepoint [1]
0
0
From randomisation (07Sep2010) to database lock (30Jul2018), up to 95 months.
Query!
Secondary outcome [2]
0
0
Best RECIST Assessment
Query!
Assessment method [2]
0
0
Best RECIST assessment is defined as CR, PR, stable disease (SD), progressive disease (PD) or not evaluable by investigator (RECIST version 1.1).
CR for target lesions (TL): Disappearance of all target lesions.
CR for non-target lesions (NTL): Disappearance of all non-target lesions and normalization of tumour marker level. All lymph nodes must be non-pathological in size (\<10mm short axis).
PR: At least a 30% decrease in the sum of diameters (SoD) of target lesions taking as reference the baseline sum diameters.
SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as references the smallest SoD while on study.
PD: At least a 20% increase in the SoD of target lesions, taking as references the smallest sum on study (this includes the baseline sum if that is the smallest on study). Also, the sum must also demonstrate an absolute increase of a least 5mm. Appearance of one or more new lesions.
Query!
Timepoint [2]
0
0
From randomization (07Sep2010) until disease progression, death or data cut-off (08Jun2013); Up to 34 months
Query!
Secondary outcome [3]
0
0
Objective Response (OR)
Query!
Assessment method [3]
0
0
OR is defined as complete response (CR) and partial response (PR). Assessed by investigator according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1. Complete Response (CR) for target lesions (TL): Disappearance of all target lesions.
Complete Response (CR) for non-target lesions (NTL): Disappearance of all non-target lesions and normalization of tumour marker level. All lymph nodes must be non-pathological in size (\<10mm short axis)
Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.
Other factors which add to the overall response of an imaging timepoint as PR are as below:-
* CR in TL, but non-CR/Non-PD in NTL leads to PR
* CR in TL, but not evaluated NTL leads to PR
* PR in TL, but non-PD NTL or not all evaluated NTL leads to PR
Query!
Timepoint [3]
0
0
Post baseline tumour-imaging was performed at Week 8, 16, 24, 32, 40, 48, 56 and then every 12 weeks (Until final data-base lock on 30 Jul 2018; Up to 95 months)
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
* Histologically confirmed diagnosis of HER2-overexpression breast cancer
* Stage IV metastatic disease
* Must have progressed on one prior trastuzumab treatment
* no more than one prior trastuzumab based therapy regimen (either adjuvant or first-line)
* Must have received anthracycline and/or taxane based chemotherapy for adjuvant treatment of breast cancer or first-line treatment of metastatic breast cancer
* Must have (archived) tumour tissue sample available for central re-assessment of HER2-status
* At least one measurable lesion according to RECIST 1.1.
* Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 .
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
* Prior treatment with Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor(EGFR/HER2)-targeted small molecules or antibodies other than trastuzumab
* Prior treatment with vinorelbine
* Known pre-existing interstitial lung disease
* Active brain metastases
* History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to randomisation.
* Cardiac left ventricular function with resting ejection fraction of less than 50%.
* Patients unable to comply with the protocol.
* Any contraindications for therapy with vinorelbine or trastuzumab.
* Known hypersensitivity to BIBW 2992 or the excipients of any of the trial drugs.
* Use of any investigational drug within 4 weeks of randomisation.
* Inadequate hepatic, renal and haematologic organ function
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
22/06/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
6/07/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
508
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Query!
Recruitment hospital [1]
0
0
Port Macquarie Base Hospital (PMBH) - Port Macquarie
Query!
Recruitment hospital [2]
0
0
St Vincent's Hospital Melbourne - Fitzroy
Query!
Recruitment hospital [3]
0
0
Peninsula Haematology & Oncology - Frankston
Query!
Recruitment hospital [4]
0
0
Maroondah Hospital - Ringwood East
Query!
Recruitment hospital [5]
0
0
Mount Medical Centre - Perth
Query!
Recruitment postcode(s) [1]
0
0
2444 - Port Macquarie
Query!
Recruitment postcode(s) [2]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [3]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [4]
0
0
3135 - Ringwood East
Query!
Recruitment postcode(s) [5]
0
0
6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Iowa
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New York
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
North Carolina
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Pennsylvania
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Utah
Query!
Country [10]
0
0
Argentina
Query!
State/province [10]
0
0
Buenos Aires
Query!
Country [11]
0
0
Argentina
Query!
State/province [11]
0
0
Capital Federal
Query!
Country [12]
0
0
Argentina
Query!
State/province [12]
0
0
Ciudad Autonoma de Bs As
Query!
Country [13]
0
0
Argentina
Query!
State/province [13]
0
0
Rosario
Query!
Country [14]
0
0
Austria
Query!
State/province [14]
0
0
Linz
Query!
Country [15]
0
0
Austria
Query!
State/province [15]
0
0
Wien
Query!
Country [16]
0
0
Belarus
Query!
State/province [16]
0
0
Grodno
Query!
Country [17]
0
0
Belarus
Query!
State/province [17]
0
0
Minsk Region
Query!
Country [18]
0
0
Belarus
Query!
State/province [18]
0
0
Minsk
Query!
Country [19]
0
0
Belarus
Query!
State/province [19]
0
0
Vitebsk
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Bruxelles
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Edegem
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Liège
Query!
Country [23]
0
0
Brazil
Query!
State/province [23]
0
0
Cachoeiro de Itapemirim
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
Curitiba
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Ijui
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
Porto Alegre
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Rio de Janeiro
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Santo André
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
Sao Paulo
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
British Columbia
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
New Brunswick
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Ontario
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Quebec
Query!
Country [34]
0
0
Chile
Query!
State/province [34]
0
0
Temuco
Query!
Country [35]
0
0
China
Query!
State/province [35]
0
0
Beijing
Query!
Country [36]
0
0
China
Query!
State/province [36]
0
0
Changchun
Query!
Country [37]
0
0
China
Query!
State/province [37]
0
0
Chengdu
Query!
Country [38]
0
0
China
Query!
State/province [38]
0
0
Fuzhou
Query!
Country [39]
0
0
China
Query!
State/province [39]
0
0
Guangzhou
Query!
Country [40]
0
0
China
Query!
State/province [40]
0
0
Haerbin
Query!
Country [41]
0
0
China
Query!
State/province [41]
0
0
Hangzhou
Query!
Country [42]
0
0
China
Query!
State/province [42]
0
0
Jinan
Query!
Country [43]
0
0
China
Query!
State/province [43]
0
0
Nanjing
Query!
Country [44]
0
0
China
Query!
State/province [44]
0
0
Shanghai
Query!
Country [45]
0
0
China
Query!
State/province [45]
0
0
Tianjin
Query!
Country [46]
0
0
China
Query!
State/province [46]
0
0
Wuhan
Query!
Country [47]
0
0
Czechia
Query!
State/province [47]
0
0
Ceske Budejovice
Query!
Country [48]
0
0
Czechia
Query!
State/province [48]
0
0
Olomouc
Query!
Country [49]
0
0
Czechia
Query!
State/province [49]
0
0
Prague 2
Query!
Country [50]
0
0
Czechia
Query!
State/province [50]
0
0
Praha 4
Query!
Country [51]
0
0
Egypt
Query!
State/province [51]
0
0
Cairo
Query!
Country [52]
0
0
Egypt
Query!
State/province [52]
0
0
Mansoura
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Amiens Cedex 1
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Angers Cedex 9
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Besançon Cedex
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Bordeaux
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Clermont-Ferrand Cedex
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Le Mans
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Nantes
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Paris
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Reims
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Rennes Cedex
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
St Cloud
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Strasbourg Cedex
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Aachen
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Bonn
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Bottrop
Query!
Country [68]
0
0
Germany
Query!
State/province [68]
0
0
Deggendorf
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Erlangen
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Essen
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Hildesheim
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Köln
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Magdeburg
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
München
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Oldenburg
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Rostock
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Wuppertal
Query!
Country [78]
0
0
India
Query!
State/province [78]
0
0
Ahmedabad
Query!
Country [79]
0
0
India
Query!
State/province [79]
0
0
Amravati
Query!
Country [80]
0
0
India
Query!
State/province [80]
0
0
Bangalore
Query!
Country [81]
0
0
India
Query!
State/province [81]
0
0
Bengaluru
Query!
Country [82]
0
0
India
Query!
State/province [82]
0
0
Chennai
Query!
Country [83]
0
0
India
Query!
State/province [83]
0
0
Hyderabad
Query!
Country [84]
0
0
India
Query!
State/province [84]
0
0
Kolkata
Query!
Country [85]
0
0
India
Query!
State/province [85]
0
0
Maharagama
Query!
Country [86]
0
0
India
Query!
State/province [86]
0
0
Nagpur
Query!
Country [87]
0
0
India
Query!
State/province [87]
0
0
Nashik
Query!
Country [88]
0
0
India
Query!
State/province [88]
0
0
Pune
Query!
Country [89]
0
0
India
Query!
State/province [89]
0
0
Visakhapatnam
Query!
Country [90]
0
0
Ireland
Query!
State/province [90]
0
0
Dubliin 9
Query!
Country [91]
0
0
Ireland
Query!
State/province [91]
0
0
Dublin 4
Query!
Country [92]
0
0
Ireland
Query!
State/province [92]
0
0
Dublin 7
Query!
Country [93]
0
0
Ireland
Query!
State/province [93]
0
0
Dublin 8
Query!
Country [94]
0
0
Israel
Query!
State/province [94]
0
0
Haifa
Query!
Country [95]
0
0
Israel
Query!
State/province [95]
0
0
Jerusalem
Query!
Country [96]
0
0
Israel
Query!
State/province [96]
0
0
Kfar Saba
Query!
Country [97]
0
0
Israel
Query!
State/province [97]
0
0
Tel Hashomer
Query!
Country [98]
0
0
Israel
Query!
State/province [98]
0
0
Tel-Aviv
Query!
Country [99]
0
0
Italy
Query!
State/province [99]
0
0
Ferrara
Query!
Country [100]
0
0
Italy
Query!
State/province [100]
0
0
Milan
Query!
Country [101]
0
0
Italy
Query!
State/province [101]
0
0
Monserrato (CA)
Query!
Country [102]
0
0
Japan
Query!
State/province [102]
0
0
Kanagawa, Isehara
Query!
Country [103]
0
0
Japan
Query!
State/province [103]
0
0
Osaka, Osaka
Query!
Country [104]
0
0
Japan
Query!
State/province [104]
0
0
Tokyo, Chuo-ku
Query!
Country [105]
0
0
Korea, Republic of
Query!
State/province [105]
0
0
Goyang
Query!
Country [106]
0
0
Korea, Republic of
Query!
State/province [106]
0
0
Seoul
Query!
Country [107]
0
0
Latvia
Query!
State/province [107]
0
0
Riga
Query!
Country [108]
0
0
Lebanon
Query!
State/province [108]
0
0
Lebanon
Query!
Country [109]
0
0
Lithuania
Query!
State/province [109]
0
0
Kaunas
Query!
Country [110]
0
0
Lithuania
Query!
State/province [110]
0
0
Vilnius
Query!
Country [111]
0
0
Mexico
Query!
State/province [111]
0
0
Colonia Centro
Query!
Country [112]
0
0
Netherlands
Query!
State/province [112]
0
0
Dordrecht
Query!
Country [113]
0
0
Netherlands
Query!
State/province [113]
0
0
Eindhoven
Query!
Country [114]
0
0
Netherlands
Query!
State/province [114]
0
0
Geleen
Query!
Country [115]
0
0
Netherlands
Query!
State/province [115]
0
0
Heerlen
Query!
Country [116]
0
0
Netherlands
Query!
State/province [116]
0
0
Maastricht
Query!
Country [117]
0
0
Netherlands
Query!
State/province [117]
0
0
Zwolle
Query!
Country [118]
0
0
Peru
Query!
State/province [118]
0
0
Cusco
Query!
Country [119]
0
0
Peru
Query!
State/province [119]
0
0
Lima
Query!
Country [120]
0
0
Peru
Query!
State/province [120]
0
0
Miraflores
Query!
Country [121]
0
0
Peru
Query!
State/province [121]
0
0
Trujillo
Query!
Country [122]
0
0
Poland
Query!
State/province [122]
0
0
Bialystok
Query!
Country [123]
0
0
Poland
Query!
State/province [123]
0
0
Bytom
Query!
Country [124]
0
0
Poland
Query!
State/province [124]
0
0
Gdansk
Query!
Country [125]
0
0
Poland
Query!
State/province [125]
0
0
Lodz
Query!
Country [126]
0
0
Poland
Query!
State/province [126]
0
0
Lublin
Query!
Country [127]
0
0
Poland
Query!
State/province [127]
0
0
Olsztyn
Query!
Country [128]
0
0
Poland
Query!
State/province [128]
0
0
Poznan
Query!
Country [129]
0
0
Poland
Query!
State/province [129]
0
0
Warsaw
Query!
Country [130]
0
0
Portugal
Query!
State/province [130]
0
0
Coimbra
Query!
Country [131]
0
0
Portugal
Query!
State/province [131]
0
0
Lisboa
Query!
Country [132]
0
0
Portugal
Query!
State/province [132]
0
0
Porto
Query!
Country [133]
0
0
Russian Federation
Query!
State/province [133]
0
0
Kazan
Query!
Country [134]
0
0
Russian Federation
Query!
State/province [134]
0
0
Moscow
Query!
Country [135]
0
0
Russian Federation
Query!
State/province [135]
0
0
Ryazan
Query!
Country [136]
0
0
Russian Federation
Query!
State/province [136]
0
0
Saint Petersburg
Query!
Country [137]
0
0
Singapore
Query!
State/province [137]
0
0
Singapore
Query!
Country [138]
0
0
Slovakia
Query!
State/province [138]
0
0
Bardejov
Query!
Country [139]
0
0
Slovakia
Query!
State/province [139]
0
0
Bratislava
Query!
Country [140]
0
0
Slovakia
Query!
State/province [140]
0
0
Poprad
Query!
Country [141]
0
0
Slovenia
Query!
State/province [141]
0
0
Ljubljana
Query!
Country [142]
0
0
South Africa
Query!
State/province [142]
0
0
Johannesburg
Query!
Country [143]
0
0
South Africa
Query!
State/province [143]
0
0
Kraaifontein
Query!
Country [144]
0
0
South Africa
Query!
State/province [144]
0
0
Port Elizabeth
Query!
Country [145]
0
0
South Africa
Query!
State/province [145]
0
0
Pretoria
Query!
Country [146]
0
0
South Africa
Query!
State/province [146]
0
0
Rondebosch, Cape Town
Query!
Country [147]
0
0
Spain
Query!
State/province [147]
0
0
Barcelona
Query!
Country [148]
0
0
Spain
Query!
State/province [148]
0
0
Las Palmas de Gran Canaria
Query!
Country [149]
0
0
Spain
Query!
State/province [149]
0
0
Madrid
Query!
Country [150]
0
0
Spain
Query!
State/province [150]
0
0
Santiago de Compostela
Query!
Country [151]
0
0
Spain
Query!
State/province [151]
0
0
Toledo
Query!
Country [152]
0
0
Spain
Query!
State/province [152]
0
0
Valencia
Query!
Country [153]
0
0
Sri Lanka
Query!
State/province [153]
0
0
Maharashtra
Query!
Country [154]
0
0
Taiwan
Query!
State/province [154]
0
0
Changhua
Query!
Country [155]
0
0
Taiwan
Query!
State/province [155]
0
0
Kaohsiung
Query!
Country [156]
0
0
Taiwan
Query!
State/province [156]
0
0
Taichung
Query!
Country [157]
0
0
Taiwan
Query!
State/province [157]
0
0
Tainan
Query!
Country [158]
0
0
Taiwan
Query!
State/province [158]
0
0
Taipei
Query!
Country [159]
0
0
Taiwan
Query!
State/province [159]
0
0
Taoyuan County
Query!
Country [160]
0
0
Turkey
Query!
State/province [160]
0
0
Ankara
Query!
Country [161]
0
0
Turkey
Query!
State/province [161]
0
0
Izmir
Query!
Country [162]
0
0
United Kingdom
Query!
State/province [162]
0
0
Dundee
Query!
Country [163]
0
0
United Kingdom
Query!
State/province [163]
0
0
London
Query!
Country [164]
0
0
United Kingdom
Query!
State/province [164]
0
0
Sutton
Query!
Country [165]
0
0
United Kingdom
Query!
State/province [165]
0
0
Woolwich, London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Boehringer Ingelheim
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
To investigate the efficacy and safety of BIBW 2992 in combination with vinorelbine i.v. chemotherapy as treatment in patients with HER2-overexpressing, metastatic breast cancer, who failed one prior trastuzumab (Herceptin®) treatment
Query!
Trial website
https://clinicaltrials.gov/study/NCT01125566
Query!
Trial related presentations / publications
Harbeck N, Huang CS, Hurvitz S, Yeh DC, Shao Z, Im SA, Jung KH, Shen K, Ro J, Jassem J, Zhang Q, Im YH, Wojtukiewicz M, Sun Q, Chen SC, Goeldner RG, Uttenreuther-Fischer M, Xu B, Piccart-Gebhart M; LUX-Breast 1 study group. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol. 2016 Mar;17(3):357-366. doi: 10.1016/S1470-2045(15)00540-9. Epub 2016 Jan 26.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Boehringer Ingelheim
Query!
Address
0
0
Boehringer Ingelheim
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01125566
Download to PDF